1. Home
  2. NAMS vs KAI Comparison

NAMS vs KAI Comparison

Compare NAMS & KAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • KAI
  • Stock Information
  • Founded
  • NAMS 2019
  • KAI 1991
  • Country
  • NAMS Netherlands
  • KAI United States
  • Employees
  • NAMS N/A
  • KAI N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • KAI Industrial Machinery/Components
  • Sector
  • NAMS Health Care
  • KAI Industrials
  • Exchange
  • NAMS Nasdaq
  • KAI Nasdaq
  • Market Cap
  • NAMS 3.1B
  • KAI 3.6B
  • IPO Year
  • NAMS N/A
  • KAI N/A
  • Fundamental
  • Price
  • NAMS $36.14
  • KAI $303.84
  • Analyst Decision
  • NAMS Strong Buy
  • KAI Buy
  • Analyst Count
  • NAMS 10
  • KAI 2
  • Target Price
  • NAMS $43.70
  • KAI $340.00
  • AVG Volume (30 Days)
  • NAMS 1.4M
  • KAI 138.2K
  • Earning Date
  • NAMS 11-06-2025
  • KAI 10-28-2025
  • Dividend Yield
  • NAMS N/A
  • KAI 0.47%
  • EPS Growth
  • NAMS N/A
  • KAI N/A
  • EPS
  • NAMS N/A
  • KAI 8.98
  • Revenue
  • NAMS $64,006,000.00
  • KAI $1,024,121,000.00
  • Revenue This Year
  • NAMS N/A
  • KAI N/A
  • Revenue Next Year
  • NAMS $1.67
  • KAI $5.10
  • P/E Ratio
  • NAMS N/A
  • KAI $33.82
  • Revenue Growth
  • NAMS 762.15
  • KAI 1.74
  • 52 Week Low
  • NAMS $14.06
  • KAI $270.73
  • 52 Week High
  • NAMS $41.47
  • KAI $429.95
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 60.09
  • KAI 52.36
  • Support Level
  • NAMS $34.34
  • KAI $289.18
  • Resistance Level
  • NAMS $37.21
  • KAI $306.46
  • Average True Range (ATR)
  • NAMS 2.47
  • KAI 10.04
  • MACD
  • NAMS -0.34
  • KAI 2.03
  • Stochastic Oscillator
  • NAMS 46.32
  • KAI 82.10

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About KAI Kadant Inc

Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.

Share on Social Networks: